Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond Inzucchi SE; McGuire DKCirculation 2008[Jan]; 117 (4): 574-84This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin system, which include the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors. In addition, we briefly survey several novel drug classes in development, provide summary recommendations for glucose-lowering regimens in specific patient types, underscore the importance of nonglucose cardiovascular risk reduction strategies, and comment on present and future considerations for the regulatory review of diabetes drugs.|Diabetes Mellitus/*drug therapy[MESH]|Dipeptidyl Peptidase 4[MESH]|Dipeptidyl-Peptidase IV Inhibitors[MESH]|Glucagon-Like Peptide 1/analogs & derivatives/therapeutic use[MESH]|Humans[MESH]|Hypoglycemic Agents/therapeutic use[MESH]|Incretins/*analogs & derivatives/therapeutic use[MESH]|Protease Inhibitors/therapeutic use[MESH] |
